Tissue-specific heterogeneity among mammalian acetylcholinesterases (AChE) has been associated with 3 alternative splicing of the primary AChE gene transcript. We have previously demonstrated that human AChE DNA encoding the brain and muscle AChE form and bearing the 3 exon E6 (ACHE-E6) induces accumulation of catalytically active AChE in myotomes and neuromuscular junctions (NMJs) of 2-and 3-day-old Xenopus embryos. Here, we explore the possibility that the 3-terminal exons of two alternative human AChE cDNA constructs include evolutionarily conserved tissue-recognizable elements. To this end, DNAs encoding alternative human AChE mRNAs were microinjected into cleaving embryos of Xenopus laevis. In contrast to the myotomal expression demonstrated by ACHE-E6, DNA carrying intron I4 and alternative exon E5 (ACHE-I4/E5) promoted punctuated staining of epidermal cells and secretion of AChE into the external medium. Moreover, ACHE-E6-injected embryos displayed enhanced NMJ development, whereas ACHE-I4/E5-derived enzyme was conspicuously absent from muscles and NMJs and its expression in embryos had no apparent effect on NMJ development. In addition, cell-associated AChE from embryos injected with ACHE-I4/E5 DNA was biochemically distinct from that encoded by the muscle-expressible ACHE-E6, displaying higher electrophoretic mobility and greater solubility in low-salt buffer. These findings suggest that alternative 3-terminal exons dictate tissue-specific accumulation and a particular biological role(s) of AChE, associate the 3 exon E6 with NMJ development, and indicate the existence of a putative secretory AChE form derived from the alternative I4/E5 AChE mRNA.
Acetylcholinesterase (AChE) is accumulated at neuromuscular junctions (NMJs) (25) , where it serves a vital function in modulating cholinergic neurotransmission (reviewed in reference 31). The molecular mechanisms by which AChE and other synaptic proteins accumulate in the NMJ are poorly understood. Compartmentalized transcription and translation in and around the junctional nuclei probably contribute to the NMJ localization of AChE (9) . However, the high concentration of AChE at NMJs suggests that an additional step(s) may be required to actively accumulate this molecule in its ultimate synaptic destination. In that case, it is possible to postulate the existence of a unique molecular tag identifying some AChE forms as NMJ bound. We have previously offered evidence that an evolutionarily conserved NMJ-recognizable signal is embedded within the primary amino acid sequence of the major brain and muscle (brain-muscle) form of AChE (1) . In the present report, we trace this signal as derived from an alternative 3Ј exon in the human AChE gene.
In addition to its synaptic location, AChE is known to exist in several nonneuronal cell types, including epidermal and hematopoietic cells (31) . Recent studies have correlated this particular tissue distribution of AChE with the 3Ј alternative splicing patterns of the mRNA transcripts encoding the AChE protein. The dominant brain-muscle AChE form found in NMJs (AChE-T) was shown to be encoded by an mRNA carrying exon E1 and the invariant coding exons E2, E3, and E4, spliced to alternative exon E6 (1, 15) . AChE mRNA bearing exons E1 through E4 and alternative exon E5 encodes the glycolipid phosphatidylinositol (GPI)-linked form of AChE characteristic of vertebrate erythrocytes (AChE-H) (13, 16 ). An additional readthrough mRNA species retaining the intronic sequence I4 located immediately 3Ј to exon E4 was previously observed in rodent bone marrow and erythroleukemic cells (13, 16) and in various tumor cell lines of human origin (11) . The tissue-specific posttranscriptional and posttranslational management of AChE mRNA and its polypeptide products raised the question of whether alternative 3Ј exons and/or C-terminal peptides play a role in mediating the accumulation of AChE in NMJs as opposed to other tissues expressing this enzyme.
To examine the molecular mechanisms underlying the tissue-specific accumulation patterns of AChE, we established an in vivo model for the expression of alternative human AChEs in transiently transgenic embryos of Xenopus laevis. Placed downstream of the cytomegalovirus (CMV) promoter-enhancer unit (32) and microinjected into fertilized eggs of X. laevis, DNA carrying the invariant coding exons and alternative exon E6 (ACHE-E6) directed the production of catalytically active AChE which accumulated in muscle cells, nerve terminals, and NMJs of 2-and 3-day-old embryos (1, 27) . Here, we have constructed an additional CMV ACHE plasmid (ACHE-I4/E5), potentially encoding the remaining two alternative AChE mRNAs, and compared its expression pattern in microinjected Xenopus embryos with that of ACHE-E6. Our findings indicate that tissue-specific accumulation of AChE may be dictated by alternative splicing of AChE mRNAs, that the 3Ј-terminal exon E6 plays an essential role in accumulation of AChE in NMJs, where it enhances NMJ development, and that the readthrough AChE mRNA may engender a unique secre-
RESULTS
Alternative mRNAs dictate specific accumulation of AChE in muscle or epidermis. To examine the ability of alternative splicing to account for tissue-specific accretion of AChE, in vitro-fertilized Xenopus eggs were microinjected with 1 ng of ACHE-E6 or ACHE-I4/E5 DNA (Fig. 1) . The resultant embryos were raised for 2 to 3 days, fixed, and stained for catalytically active enzyme. Following injection of ACHE-E6, encoding the brain-muscle form of AChE, 2-day-old tailbud embryos displayed conspicuous overexpression of AChE in the developing myotomes (Fig. 2, top panels) . Myotomal overexpression was primarily observed as pronounced longitudinal staining along the plane of the muscle fibers between the vertical bands representing natural intersomitic accumulations of AChE. With the exception of brain tissues, no other tissues displayed consistently or prominently enhanced staining. However, myotomal overexpression of AChE was clearly mosaic, varying in intensity within and between individual somites. Uninjected control embryos displayed the characteristic transverse staining along the junctions between somites but only faint staining within the myotomes (Fig. 2, top panels) .
In contrast to the striking accumulation of ACHE-E6-derived AChE in myotomes, we did not observe any enhancement of staining in myotomes of embryos injected with ACHE-I4/E5. Rather, we noted pronounced punctuated staining of the epidermis which was never seen in uninjected embryos (Fig. 2, bottom panels) . These differential staining patterns were probably not due to variable levels of AChE mRNA, as whole-mount in situ hybridization (9) revealed similar ubiquitous distributions of both transcripts (data not shown). Epidermal staining could be observed over the entire body along both the rostral-caudal and dorsal-ventral axes. Intersomitic staining was unaffected by overexpression of ACHE-I4/E5. Although limited epidermal staining was occasionally observed in ACHE-E6-injected embryos, this phenomenon appeared restricted to sites of particularly high myotomal expression and was considerably less well defined (Fig. 2, bottom panels) . These observations indicated that AChE derived from ACHE-E6 DNA was specifically accumulated in muscle, whereas AChE derived from ACHE-I4/E5 was accumulated in the epidermis.
ACHE-I4/E5 is excluded from the NMJ localization characteristic of ACHE-E6 and plays no role in NMJ development. Electron microscopic analysis of myotomes stained for catalytically active AChE revealed conspicuous overexpression of enzyme in NMJs of ACHE-E6-injected embryos and correlated overexpression with alterations in synaptic ultrastructure (27) . To finely examine the potential for ACHE-I4/E5-derived AChE to be similarly localized, we performed morphometric analyses of cross sections from a series of stained NMJs from DNA-injected or control uninjected embryos (Fig. 3A At least 40% of NMJs from uninjected and ACHE-I4/E5-injected embryos displayed postsynaptic lengths less than 3 m. In contrast, these small synapses were not observed in ACHE-E6-injected embryos (Fig. 4) . Rather, a class of large NMJs (Ͼ4 m) rarely observed in control or ACHE-I4/E5-injected embryos dominated in those transgenic for ACHE-E6. When the AChE-stained area was calculated as a function of postsynaptic length, ACHE-I4/E5-injected and control uninjected embryos displayed a similar, constant relationship between these parameters, whereas ACHE-E6-injected embryos displayed a higher ratio for all length categories (Fig. 4) . Thus, there appeared to be a causal correlation between AChE overexpression in muscle and enhanced postsynaptic length in individual synapses, confirmed by the lack of effect by ACHE-I4/E5. Together, these observations imply a specific role for the E6 exon in localizing AChE to NMJs and demonstrate that the effects of AChE overexpression on NMJ biogenesis are dependent on the muscle localization of the enzyme.
The I4/E5 domain directs AChE accumulation in ciliated epidermal cells and its excretion. To study the cellular and subcellular distribution of overexpressed AChE in epidermal cells from embryos injected with ACHE-I4/E5, we examined epidermis from cytochemically stained embryos by electron microscopy. Two types of cells were labelled by the electrondense crystals of the AChE reaction product: (i) ciliated cells derived from the inner, sensorial, epidermal layer and (ii) mucus-discharging secretory cells ( VOL. 15, 1995 TISSUE RETENTION SIGNALS IN AChE 3Ј EXONS 2995
3. I4/E5-derived AChE, unlike ACHE-E6, is excluded from NMJs. Two-day-old DNA-injected and control uninjected Xenopus embryos raised at 19ЊC were cytochemically stained for catalytically active AChE and examined by electron microscopy as described in Materials and Methods. Note the significantly enhanced staining, observed as dark electron-dense deposits, and increased size displayed by NMJs from ACHE-E6-injected embryos (B) as compared with those from control (A) and ACHE-I4/E5-injected (C) embryos. Shown are transverse sections of myofibers from control (D), ACHE-E6-injected (E), and ACHE-I4/E5-injected (F) embryos; note the correlation between myotomal and synaptic levels of expression. T, nerve terminal; M, muscle cell. For an explanation of the schematic diagrams, see dence and intensity of staining were higher among the ciliated cells, with some displaying massive apical accumulations of reaction product (Fig. 5 ). This irregular mosaic of heavily stained cells corresponded well to the punctuated array of stained cells observed in whole-mount embryos (Fig. 2) . In uninjected control and ACHE-E6-injected embryos, both types of epidermal cells displayed scant staining, if any (Fig.  5B , D, and F and data not shown). Ciliated cells were characterized, in addition to their cilia, by their dense cytoplasm, rich accumulation of mitochondria, and the presence of numerous small vesicles, most of which were filled with reaction product in stained cells (Fig. 5) . Crystals of reaction product were also observed, however, in the cytoplasm and increased in size and density in a graded fashion toward the apex. In contrast, secretory cells were identified on the basis of their large, distinctive, chondroitin-laden secretory vesicles (Fig. 5) (21) , some of which appeared to be fused to the plasma membrane (data not shown). In labelled secretory cells from ACHE-I4/E5-injected embryos, up to 20% of the vesicles stained positively for AChE. However, only an occasional crystal of reaction product could be observed in vesicles from uninjected or ACHE-E6-injected embryos (Fig. 5 and data not shown). No gross morphological features distinguished stained cells or vesicles in ACHE-I4/E5-injected embryos from unstained ones or from those observed in control or ACHE-E6-injected embryos.
The observation that mature secretory vesicles in epidermis of ACHE-I4/E5-injected embryos stained positively for AChE suggested that this enzyme form may be secreted along with the mucus naturally contained within these vesicles. To determine whether AChE was being excreted from the body, healthy neurula-stage embryos either injected with vector or uninjected were incubated overnight and the AChE activity found in the medium was compared with that measured in total homogenates. Only incubation medium from embryos injected with ACHE-I4/E5 DNA displayed significant AChE activity, representing up to 40% of the total measured activity (Fig. 6) . Together, these observations indicated that a property or properties intrinsic to the I4/E5-terminal exon confer(s) a signal for epidermal accumulation, polarized subcellular transport, and excretion of AChE. Transfection studies with cultured glioma cells later revealed that secretion of the ACHE-I4/E5 product is a general phenomenon (11a).
Epidermal excretion is associated with readthrough AChE mRNA. Microinjected Xenopus embryos have been shown to correctly splice intron I1 from a human AChE promoter-reporter construct to produce catalytically active AChE (1). ACHE-I4/E5 potentially leads to both the mRNA encoding the erythrocyte GPI-linked AChE, by splicing out of intron I4, and/or the complete readthrough mRNA in which the invariant exons continue directly from exon E4 into intron I4 and through it into exon E5 (11) (Fig. 7A) . To determine which AChE mRNA(s) was produced in our Xenopus embryos, we subjected total RNA extracted from 1-day-old ACHE-E6-or ACHE-I4/E5-injected embryos to RT-PCR with E4-, I4-, E5-, or E6-specific primers (Fig. 7A and see Materials and Methods). When an E6-specific primer pair was employed to analyze RNA from ACHE-E6-injected gastrulae, the expected 482-bp fragment representing full-length ACHE-E6 mRNA was reproducibly observed (Fig. 7B) . When RNA from ACHE-I4/E5-injected embryos was subjected to RT-PCR, both the invariant exon E4 and the intronic sequence I4 were detected. However, the E5-specific primer pair repeatedly failed to generate either the 479-bp fragment representing the full-length readthrough mRNA or the 399-bp fragment representing spliced E5-bearing mRNA (Fig. 7B) . A parallel reaction using control plasmid DNA and the identical E5-specific primers did yield the 479-bp band, however, validating the efficacy of this primer pair (Fig. 7B) . Moreover, this same primer pair has been successfully utilized to detect native E5-carrying mRNAs in human tissues and transfected mammalian cells (11, 11a) . These data therefore indicated that the recombinant human AChE activity induced by ACHE-E6 reflected the complete brain-muscle form of AChE, whereas heterologous AChE activity produced in Xenopus embryos from ACHE-I4/E5 was derived from a readthrough AChE mRNA which was, at least partially, truncated. This, together with the stop codon included in I4, implied that the polypeptide encoded by ACHE-I4/E5-derived mRNA in Xenopus embryos could display biochemical characteristics distinct from both brain-muscle and erythrocyte AChEs.
Unique properties of ACHE-I4/E5-derived AChE. Microinjection of 1 ng of ACHE-E6 DNA induces transiently high levels of catalytically active recombinant human AChE in Xenopus embryos (27) . When ACHE-I4/E5 was introduced into 1-to 2-cell cleaving embryos, equivalent levels and a similarly transient pattern of heterologous overexpression were observed, peaking at days 1 to 2 postfertilization and receding at day 4 or 5 ( Fig. 8A) . Overall, development of injected embryos appeared normal through gastrulation, neurulation, hatching, To compare the hydrodynamic properties of the recombinant human enzymes, we performed sequential extractions of gastrula-stage embryos into low-salt, low-salt-detergent, and high-salt buffers. AChE activity from embryos injected with ACHE-E6 DNA consistently partitioned into both the low-salt (55%) and low-salt-detergent (35%) fractions. In contrast, activity from embryos injected with ACHE-I4/E5 was 85 to 90% solubilized in the low-salt step (Fig. 8B) . In sucrose density gradient centrifugation, a single peak between 3 and 4 S was observed for the ACHE-E6-and ACHE-I4/E5-derived enzymes, both of which cosedimented with the clearly monomeric recombinant enzyme produced in bacteria (reference 27 and data not shown). This is consistent with a monomeric configuration for the cell-associated recombinant molecules. However, by nondenaturing polyacrylamide gel electrophoresis, catalytically active AChE from ACHE-I4/E5-injected embryos migrated significantly faster than the bands representing either recombinant human AChE from ACHE-E6-injected embryos or native AChE from human brain or erythrocytes (Fig. 8C) . When electrophoresis was performed in the absence of detergent, no significant shift in the migration of ACHE-I4/ E5-derived bands was observed, suggesting that this molecule represented a nonhydrophobic AChE species (Fig. 8C) .
DISCUSSION
In transiently transgenic X. laevis embryos, AChE mRNA bearing the alternative 3Ј exon E6 induced specific accumulation of human AChE in muscle and NMJs and enhanced NMJ development. Replacement of E6 with an in-frame pseudointronic sequence of similar size directed production of equal amounts of a soluble enzyme species that was amassed in epidermal cells and excreted into the external culture medium and which was not incorporated into muscle or NMJs and did not affect their development. These observations suggest that the 3Ј-terminal exons encoding the various AChE subtypes played indispensable roles in their NMJ or epidermal localization.
Differential posttranscriptional management of alternative AChE forms. The native human AChE promoter includes consensus recognition sites for transcription factors indicative of tissue-specific regulation of transcription (1). However, the CMV promoter used to direct the expression of AChE in X. laevis is pan-active (26), and our in situ hybridization suggests that it is expressed in the embryos in a nonspecific manner relatively early in development. This would explain the high levels of heterologous enzyme observed at the gastrula stage (day 1). Thus, the tissue-specific accumulation of alternative heterologous AChEs reflects differential posttranscriptional or posttranslational management of their respective RNA and/or protein products. Stabilization of AChE mRNA was recently shown to account for the increased AChE activity accompanying differentiation of cultured myoblasts (7). Our present observations add differential stability of alternative AChE polypeptides as a potential factor in the tissue-specific accumulation of these AChE forms.
In vivo, AChE is subject to tissue-specific and developmentally regulated posttranscriptional and posttranslational processing, which gives rise to a complex array of molecular forms varying in their extents of oligomeric assembly, association FIG. 6 . ACHE-I4/E5 but not ACHE-E6 is excreted into the external medium. Fractions of total recovered AChE activity (medium plus whole-cell extract) in the external growth medium are presented for 20 DNA-injected (E6 and I4/E5) or control (Uninj) embryos following incubation of neurula-stage embryos overnight (day 13day 2) in fresh buffer. Note that only embryos expressing ACHE-I4/E5 DNA displayed significant secretion of AChE into the surrounding medium. For an explanation of the schematic diagrams, see Fig. 1 .
B.
A. with noncatalytic subunits, hydrodynamic properties, and sites of subcellular localization (17) . One level at which this diversity is controlled appears to be alternative splicing of 3Ј exons (11, 15, 28) . Transfections of AChE-coding sequences into mammalian cells indicated that alternative splicing alone could account for these multiple molecular forms of AChE (5, 12, 14, 16) . Our results extend these conclusions by demonstrating that alternative splicing may dictate the final complement of specific AChE catalytic subunits available to particular cell types through selective management of specific AChE mRNAs and AChE polypeptides. Translated or nontranslated AChE mRNA, stable or unstable AChE mRNA, or polypeptides may dictate the final complement of specific AChE catalytic subunits expressed in particular cell types. 3 exon E6 defines an indispensable motif for synaptic accumulation of AChE. Compartmentalized biosynthesis of the nicotinic acetylcholine receptor (reference 18 and reviewed in reference 4) as well as other NMJ proteins (22, 24) suggests that an intricate network of factors are at work to produce and localize NMJ proteins around junctional regions prior to their active accumulation at the NMJ. This network could potentially include cis-acting elements intrinsic to the mRNA or primary amino acid sequences of NMJ-targeted proteins as well as trans-acting cellular components capable of anchoring or translocating these molecules within the muscle. An example of a trans-acting factor controlling the translocation and subcellular anchoring of specific mRNAs is the 69-kDa protein associated with the developmentally regulated accumulation of two vegetal mRNAs in Xenopus oocytes (23) . Our present findings demonstrate that the transiently transgenic embryos of X. laevis can be further employed to search for cis-and transacting factors controlling the management of proteins from heterologous species. Recent work demonstrating the spatially restricted biosynthesis of AChE in avian muscle predicts the existence of localized cellular factors recognizing AChE and/or its encoding mRNA (9) . In the present study, we observed that exon E6 and/or its encoded peptide participate in forming a recognition signal(s) through which such putative cellular elements might mediate accumulation and subcellular localization of AChE. Search of the Genetics Computer Group data bank did not reveal significant homologies between the E6-encoded peptide and any protein except the related acetylcholine-hydrolyzing enzyme butyrylcholinesterase. However, it is interesting that this enzyme, which has high homology (56%) to AChE in the corresponding C-terminal domain, also accumulated in NMJs of microinjected Xenopus embryos (reference 29 and unpublished observations). Moreover, both these enzymes are also found in brain nerve-nerve synapses (29) . Thus, our findings suggest that exon E6 defines a conserved motif for muscle accumulation and trafficking of cholinesterases into synapses but not necessarily a general signal for targeting proteins to NMJs. Further experiments will be required to determine whether E6 is sufficient to direct synaptic accumulation of unrelated proteins to the NMJ as well.
A novel I4/E5-derived readthrough form of human AChE. An mRNA representing the I4 readthrough transcript in mouse tissues was reported but is considered absent in human cells. This difference was attributed to an inherent property of the human AChE nucleotide sequence (16) . Nonetheless, we have recently observed, using RT-PCR and I4-specific primers, mRNA carrying the retained I4 sequence, in addition to E5 and E6, in several tumor cell lines of human origin (11) as well as in numerous mouse tissues (data not shown). That study did not, however, reveal whether this mRNA species is translated into protein and what the properties of the putative human readthrough AChE might be. In the present work, RT-PCR indicated the presence of a potentially truncated readthrough mRNA derived from ACHE-I4/E5 in microinjected Xenopus embryos. The protein translated from this readthrough RNA would lack the cleavable hydrophobic E5 stretch, precluding GPI linkage and leaving the relatively hydrophilic I4-encoded peptide. This could explain the high solubility of catalytically active AChE derived from ACHE-I4/E5 DNA.
When DNA encoding the mouse readthrough mRNA, where a nonsense codon appears 40 nucleotides downstream of the E4/I4 boundary, was expressed in COS cells, 97% of the total activity was soluble and secreted into the culture medium (16) . The present study suggests that a truncated human readthrough AChE mRNA might also be translatable, giving rise to a catalytically active, nonmuscle, secretory form of AChE in X. laevis. However, the overall timing and levels of ACHE-I4/E5 expression in the embryos as assessed in total homogenates indicate generally similar stability of its mRNA and protein product as compared with those derived from ACHE-E6. Therefore, these observations may offer the first indications for the existence of yet another stable human AChE subtype representing the common exons E2, E3, and E4 and the pseudointron I4.
The human readthrough AChE mRNA (11) carries a 9-nucleotide sequence (5Ј-ACCTGCCCA-3Ј) beginning 18 nucleotides downstream of the I4/E5 boundary that is identical (in 8 of 9 bp) to that contained within a 19-bp consensus mRNAdestabilizing site (3). This sequence mediates endonucleolytic cleavage of RNA in X. laevis and Drosophila melanogaster and could explain the appearance of a truncated RNA. Indeed, when DNA encoding GPI-linked Drosophila AChE was expressed in microinjected Xenopus oocytes, a hydrophobic, but nonglypiated, membrane-associated enzyme was obtained.
However, deletion of the sequence encoding the 27-aminoacid hydrophobic C-terminal peptide yielded a soluble, secreted AChE (6) . Experiments to determine the precise 3Ј and/or C-terminal limit of ACHE-I4/I5-derived mRNA and its polypeptide product are currently in progress.
Secretory AChE-I4/E5 may reflect an in vivo entity. It is yet uncertain whether generation of the unusual ACHE-I4/E5-derived protein and its accumulation in epidermis reflect natural events in the biosynthesis of human AChE or an anomalous expression pattern for this AChE in X. laevis. However, the putative AChE generated from ACHE-I4/E5 in X. laevis is catalytically indistinguishable from the ACHE-E6-derived enzyme (26a) and should be very close in size to the 583-aminoacid brain-muscle form. Therefore, the presence of such a discrete molecule in native human tissues would be difficult to detect and might easily go unnoticed. Moreover, a soluble AChE form with a distinct migration profile in isoelectric focussing was observed in the cerebrospinal fluid of patients with Alzheimer's disease (19) , and soluble AChE monomers were reported in the serum of patients with carcinomas (33) . Thus, the distinct migration of the short readthrough AChE derived from ACHE-I4/E5 in nondenaturing gel electrophoresis may provide a tool to search for a naturally occurring form of this enzyme species in humans.
In conclusion, we have used microinjected Xenopus embryos for transgenic overexpression of DNA constructs encoding variable C-terminal alternative forms of AChE. We established an NMJ-accumulating role for the 3Ј exon E6 and observed epidermal expression and active secretion for human AChE encoded by a construct carrying the alternative 3Ј region, I4/ E5. ACHE-I4/E5 displayed hydrophilic properties and fast electrophoretic migration, reminiscent of a human AChE form reported in Alzheimer's disease. It was further excluded from muscle and NMJ structures and, in contrast with ACHE-E6, did not enhance NMJ development. These findings demonstrate that alternative 3Ј exons in the AChE gene specify distinct tissue-recognizable signals and suggest the use of transiently transgenic Xenopus embryos for disclosing cell type specificities and biological roles of gene products from heterologous species.
